Kallidinogenase normalizes retinal vasopermeability in streptozotocin-induced diabetic rats: Potential roles of vascular endothelial growth factor and nitric oxide

3区 · 医学

Article

作者: Takagi, Hitoshi ; Suzuma, Kiyoshi ; Lu, Chunmei ; Matsumoto, Yukiharu ; Kato, Noriaki ; Hou, Yunlong ; Nagano, Hiroshi ; Lu, Zhenhui

We studied the suppressant effect of kallidinogenase on retinal vascular permeability and vascular endothelial growth factor (VEGF) in diabetic rats. Diabetes was induced by intravenously injecting streptozotocin (60 mg/kg body weight) dissolved in citrate buffer. Kallidinogenase (7 microg/kg/day) was injected intravenously once daily for 21 days. The retinal vascular permeability was estimated from the amount of fluorescent dye leaking into the retina after administration of fluorescein isothiocyanate-conjugated dextran. VEGF in intraocular fluids was quantified by an enzyme-linked immunosorbent assay. The amounts of nitrite and nitrate in the retina were quantified by a fluorescence method using 2,3-diaminonaphthalene. Retinal vascular permeability in the diabetic control group was about 5.5 times higher than in the normal control group (P<0.001). Kallidinogenase suppressed the increased retinal vascular permeability. In the diabetic control group, the VEGF level was three times that of the normal control group (diabetic control group, 160+/-12 pg/ml; normal control group, 54+/-9 pg/ml; P<0.001). The VEGF concentration in the kallidinogenase-treated group was 120+/-12 pg/ml (P<0.05). In the diabetic control group, the amounts of nitrite and nitrate in the retina were lower by about 2.6-fold, compared with the normal control group (P<0.05). Kallidinogenase almost normalized the decreases in nitrite and nitrate in the retina. The current study showed beneficial effects of kallidinogenase on increased retinal vascular permeability and VEGF in diabetic rats, suggesting that kallidinogenase may be effective for simple retinopathy in patients with diabetes.

1985-04-01·Clinical Otolaryngology

Treatment of sudden deafness: carbon dioxide and oxygen inhalation and steroids

Article

作者: H. Edamatsu ; M. Hasegawa ; N. Kurita ; T. Oku ; I. Watanabe ; T. Nigauri

The results of treating 86 patients with sudden deafness are reviewed in this paper. They were treated with intravenous ATP-2Na, Vitamin B1, B6, B12 and C, stellate ganglion block, peroral steroids, cyclandelate and Kallidinogenase. Fifty-one of 86 patients were additionally treated with carbon dioxide and oxygen inhalation. The first 35 patients (no gas inhalation group) and the latter 51 patients (gas inhalation group) were compared with each other concerning hearing improvement, and recovery rate associated with age of the patients, untreated period and effect of steroids. There was no statistical difference between the two groups with regard to these parameters.

100 项与激肽释放酶(Kyowa Pharmaceutical Industry) 相关的药物交易

登录后查看更多信息

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
脉络膜视网膜炎	日本	Kyowa Pharmaceutical Industry Co., Ltd.	1988-07-11
更年期综合症	日本	Kyowa Pharmaceutical Industry Co., Ltd.	1988-07-11
外周循环不良	日本	Kyowa Pharmaceutical Industry Co., Ltd.	1988-07-11